Chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement- and Fc-mediated cytotoxicity and apoptosis, reducing B-cell receptor signaling, autoantibody production, and ectopic germinal center activity.
Chimeric anti-CD20 monoclonal IgG1 that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, Fc-mediated ADCC, and apoptosis, reducing B-cell receptor signaling and autoantibody production.
YES
DIRECT
Rituximab binds CD20 on B cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC by effector cells, and can directly induce apoptosis of CD20+ cells.
Replicating arenavirus-based therapeutic cancer vaccine (viral vector) encoding HPV16 E6/E7 that infects antigen-presenting cells to induce strong HPV16-specific CD8+ T-cell responses; used in alternating prime-boost with HB-202.
Replication-attenuated arenavirus vector encoding HPV16 E6/E7 infects antigen-presenting cells, driving expression and presentation of E6/E7 antigens to elicit strong HPV16-specific CD8+ cytotoxic T-cell responses that target and kill HPV16-expressing tumor cells; can be used in alternating prime-boost with HB-202 to mitigate anti-vector immunity.
YES
INDIRECT
HB-201 is a therapeutic vaccine that primes HPV16 E6/E7–specific CD8+ T cells; these CTLs recognize E6-derived peptides on MHC I of HPV16+ tumor cells and kill them via perforin/granzyme and Fas/FasL pathways.
Replicating arenavirus-based therapeutic cancer vaccine (viral vector) encoding HPV16 E6/E7 that infects antigen-presenting cells to induce strong HPV16-specific CD8+ T-cell responses; used in alternating prime-boost with HB-202.
Replication-attenuated arenavirus vector encoding HPV16 E6/E7 infects antigen-presenting cells, driving expression and presentation of E6/E7 antigens to elicit strong HPV16-specific CD8+ cytotoxic T-cell responses that target and kill HPV16-expressing tumor cells; can be used in alternating prime-boost with HB-202 to mitigate anti-vector immunity.
YES
INDIRECT
Therapeutic vaccine transduces APCs to present HPV16 E7, priming E7-specific CD8+ T cells. These CTLs recognize E7-derived peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated cytolysis.
Engineered allogeneic cord blood–derived natural killer cells expressing an HLA-A*02:01–restricted T-cell receptor specific for PRAME to enable antigen-specific recognition and cytotoxic killing of PRAME-positive myeloid blasts.
Allogeneic cord blood-derived NK cells engineered to express an HLA-A*02:01-restricted T-cell receptor specific for PRAME. The TCR recognizes PRAME peptide-HLA-A*02:01 complexes on tumor cells, leading to antigen-specific NK activation and cytotoxic lysis (perforin/granzyme) of PRAME-positive myeloid blasts.
YES
DIRECT
TCR-engineered NK cells recognize PRAME peptide–HLA-A*02:01 complexes on target cells and directly kill them via perforin/granzyme-mediated cytolysis.
Replicating arenavirus-based therapeutic cancer vaccine (viral vector) encoding HPV16 E6/E7 designed to elicit HPV16-specific CD8+ T-cell responses; heterologous partner to HB-201 in an alternating prime-boost regimen.
Replicating arenavirus vector delivering genes encoding an inactivated HPV16 E6/E7 fusion protein to antigen-presenting cells, driving strong MHC I presentation and expansion of HPV16-specific CD8+ cytotoxic T cells that recognize and kill HPV16 E6/E7–expressing tumor cells; used in a heterologous prime–boost with HB-201 to mitigate anti-vector immunity.
YES
INDIRECT
Viral-vector vaccine elicits HPV16 E6–specific CD8+ T cells that recognize E6 peptides on MHC I and kill tumor cells via perforin/granzyme (and Fas–FasL) cytotoxicity.